Apr 16, 2026
This video, presented by Dr. John Campbell, discusses a prospective observational study involving 197 cancer patients who were prescribed an off-label combination of ivermectin (25 mg) and mebendazole (250 mg) daily for 90 days (0:01-4:46). The study aimed to evaluate patient-reported outcomes, safety, and adherence to this repurposed, low-cost protocol.
Key Findings:
Clinical Benefit: The study reported a Clinical Benefit Ratio (CBR) of 84.4%, which includes patients who experienced complete response, partial response, or stable disease (1:21, 9:16).
Outcomes Breakdown: Among the cohort, 32.8% had no current evidence of disease (NED), 15.6% reported tumor regression, and 36.1% maintained stable disease, while 15.6% experienced progression (9:30-9:42).
Adherence & Safety: The treatment was found to be well-tolerated, with an 86.9% adherence rate and only mild side effects (primarily gastrointestinal) reported by 25.4% of participants, most of whom were able to continue treatment (8:16, 11:58).
Dose-Response: Notably, the study observed no significant dose-response association (p = 0.91), suggesting that lower doses may be as effective as higher ones (10:13, 11:32).
Mechanisms and Discussion:
The video highlights that these drugs are not acting as antiparasitics in this context but via multiple anti-cancer mechanisms, including the inhibition of cell proliferation, angiogenesis, and mitochondrial function (16:18-17:23).
Both agents are noted for their ability to selectively target cancer stem cells and disrupt microtubule formation, leading to cell cycle arrest and apoptosis (19:24-21:34).
Dr. Campbell emphasizes that while these findings are hypothesis-generating and require validation through large-scale, randomized controlled trials, the potential for such inexpensive, repurposed therapies is significant, especially given the high costs of standard chemotherapy (13:57-15:13).